Corvus Pharmaceuticals Inc (CRVS) Stock Analysis
Verdict: WATCH (do not buy)
Soquelitinib's dual oncology-immunology potential and 3.5-year cash runway offset near-term earnings misses and 30-day price momentum loss.
Investment score: 45/100
Analysis as of
Is Corvus Pharmaceuticals Inc stock worth reviewing? AI model thesis
Corvus Pharmaceuticals is a pre-revenue clinical biotech supported by $215.2M in cash and short-term investments, funding operations into Q2 2028. While Phase 3 trial progress for soquelitinib in T-cell lymphoma provides long-term optionality, negative technical momentum (-26.4% in 30 days) and distant clinical inflection points in Q1 2027 warrant a cautious Hold stance.
7-factor investment score
- Valuation: 40/100 (weight 20%)
- Financial Health: 55/100 (weight 15%)
- Technical Momentum: 30/100 (weight 15%)
- Earnings Quality: 35/100 (weight 15%)
- Insider Sentiment: 65/100 (weight 10%)
- Analyst Consensus: 75/100 (weight 10%)
- Risk-Adjusted Return: 35/100 (weight 15%)
Corvus Pharmaceuticals Inc opportunities and risks
What speaks for CRVS
- Soquelitinib Phase 3 Registration Trial in PTCL
What speaks against CRVS
- Binary Clinical Trial Failure for Soquelitinib
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| CRVS | n/a | 0.0x | n/a | 0.0% | 0.0% | -5.2% |
| SVRA | n/a | 0.0x | n/a | 0.0% | 0.0% | -11.6% |
| ODTX | n/a | 0.0x | n/a | 0.0% | 0.0% | -8.0% |
| KURA | n/a | 12.2x | n/a | 94.7% | -384.3% | -12.5% |
| JBIO | n/a | 0.0x | n/a | 0.0% | 0.0% | -14.9% |
| SANA | n/a | 0.0x | n/a | 0.0% | 0.0% | -17.1% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -12.5% |
Frequently asked questions about Corvus Pharmaceuticals Inc (CRVS)
Is CRVS stock a good investment?
The cached TradeMates AI model rates Corvus Pharmaceuticals Inc as WATCH (do not buy) with an investment score of 45/100. Corvus Pharmaceuticals is a pre-revenue clinical biotech supported by $215.2M in cash and short-term investments, funding operations into Q2 2028. While Phase 3 trial progress for soquelitinib in T-cell lymphoma provides long-term optionality, negative technical momentum (-26.4% in 30 days) and distant clinical inflection points in Q1 2027 warrant a cautious Hold stance. This is algorithmic model output, not personal investment advice.
Is CRVS stock a buy?
The TradeMates model verdict for CRVS is WATCH (do not buy) with an investment score of 45/100. Treat this as a model signal to review, not a personal buy recommendation.